NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, which is for the treatment of patients suffering from severe Parkinson's disease; ND0612L, which is for the treatment of patients at the moderate stage of Parkinson's disease, and ND0701, which is an apomorphine-based product. The Company is also developing a product candidate, ND0801, to treat cognition disorders associated with CNS diseases. The Company's delivery devices include CRONO ND, which is a fixed-dose belt pump, and CRONO Twin ND, which is an adjustable belt pump.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NDRM
- Previous Close: $23.35
- 50 Day Moving Average: $23.50
- 200 Day Moving Average: $19.55
- 52-Week Range: $11.83 - $25.45
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.50
- P/E Growth: 0.00
- Market Cap: $507.16M
- Outstanding Shares: 21,720,000
- Beta: 0.94
- Return on Equity: -32.12%
- Return on Assets: -30.45%
Companies Related to NeuroDerm:
- Current Ratio: 15.77%
- Quick Ratio: 15.77%
What is NeuroDerm's stock symbol?
NeuroDerm trades on the NASDAQ under the ticker symbol "NDRM."
Where is NeuroDerm's stock going? Where will NeuroDerm's stock price be in 2017?
3 analysts have issued 1-year target prices for NeuroDerm's stock. Their predictions range from $30.00 to $42.00. On average, they expect NeuroDerm's share price to reach $36.00 in the next year.
When will NeuroDerm announce their earnings?
NeuroDerm is scheduled to release their next quarterly earnings announcement on Wednesday, March, 29th 2017.
What are analysts saying about NeuroDerm stock?
Here are some recent quotes from research analysts about NeuroDerm stock:
According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (2/14/2017)
Oppenheimer Holdings, Inc. analysts commented, "NeuroDerm reported a 4Q15 net loss/EPS of ($6.7M)/($0.31) compared to our estimates ($7.6M)/($0.35) and consensus ($6.4M)/($0.29). NeuroDerm reiterated its timeline for the initiation and expected data readouts for its multiple development programs, including top line results for the pilot PK study of ND0612H (in EU) expected 2Q16, and top line results of the Phase II efficacy trial of ND0612H in the US in 2H16. In line with previous guidance by NDRM, Cane S.p.A. has responded to the FDA letter listing manufacturing deficiencies, and so it seems that this issue has been overcome." (4/1/2016)
Who owns NeuroDerm stock?
NeuroDerm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (3.07%), Menora Mivtachim Holdings LTD. (2.66%), Franklin Resources Inc. (2.30%), Arrowpoint Asset Management LLC (1.46%), Senzar Asset Management LLC (0.86%) and Opaleye Management Inc. (0.53%).
Who sold NeuroDerm stock? Who is selling NeuroDerm stock?
NeuroDerm's stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD. and Menta Capital LLC.
Who bought NeuroDerm stock? Who is buying NeuroDerm stock?
NeuroDerm's stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Acuta Capital Partners LLC, Senzar Asset Management LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Arrowpoint Asset Management LLC, State Street Corp and Pyrrho Capital Management LP.
How do I buy NeuroDerm stock?
Shares of NeuroDerm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NeuroDerm stock cost?
One share of NeuroDerm stock can currently be purchased for approximately $23.35.